Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study.
Adult
Aged
Antineoplastic Agents
/ administration & dosage
Biomarkers
Drug Resistance, Neoplasm
Female
Histone Deacetylase Inhibitors
/ administration & dosage
Hodgkin Disease
/ diagnosis
Humans
Hydroxamic Acids
/ administration & dosage
Kaplan-Meier Estimate
Male
Middle Aged
Positron Emission Tomography Computed Tomography
Positron-Emission Tomography
Recurrence
Retreatment
Sulfonamides
/ administration & dosage
Treatment Outcome
Young Adult
Hodgkin lymphoma
Resminostat
epigenetics
histone deacetylase
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
pubmed:
31
8
2018
medline:
1
5
2020
entrez:
31
8
2018
Statut:
ppublish
Résumé
This open-label, single-arm phase II study examined efficacy, safety, pharmacokinetics, and biomarkers of histone deacetylase (HDAC) inhibitor resminostat in patients with relapsed or refractory Hodgkin lymphoma. Thirty-seven heavily pretreated patients received 600 (19 patients) or 800 mg (18 patients) oral resminostat daily for the initial 5 days of 14-day treatment cycles. Objective response rate (ORR) (primary) was 34% reaching disease control in 54% patients. Most patients (69%) showed reduced tumor size and reduced [
Identifiants
pubmed: 30160566
doi: 10.1080/10428194.2018.1492122
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers
0
Histone Deacetylase Inhibitors
0
Hydroxamic Acids
0
Sulfonamides
0
resminostat
1578EUB98L
Types de publication
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM